A systematic review of the treatment studies in Huntington's disease since 1990

被引:68
作者
Bonelli, Raphael M. [1 ]
Hofmann, Peter [1 ]
机构
[1] Graz Med Univ, Univ Clin Psychiat, A-8036 Graz, Austria
关键词
chorea; Huntington's disease; neuroleptics; neuroprotection;
D O I
10.1517/14656566.8.2.141
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Huntington's disease (HD) is an autosomal dominant, inherited, neuropsychiatric disease that gives rise to progressive motor, cognitive and behavioural symptoms. Current drug therapy has no effect on the progression of disability, and the need for any pharmacological treatment should be carefully considered. Hyperkinesias and psychiatric symptoms may respond well to pharmacotherapy, but neuropsychological deficits and dementia remain untreatable. Pharmacological intervention in the treatment of the movement disorder of HD is aimed at restoring the balance of neurotransmitters in the basal ganglia. A surprising amount of current drug therapy of HD in clinical practice is based on studies published before 1990. The authors conducted a systematic review of pharmacological therapy in HID using the available papers that were published between 1990 and 2006.
引用
收藏
页码:141 / 153
页数:13
相关论文
共 146 条
[61]   Therapeutic opportunities in polyglutamine disease [J].
Hughes, RE ;
Olson, JM .
NATURE MEDICINE, 2001, 7 (04) :419-423
[62]   Long-term effects of tetrabenazine in hyperkinetic movement disorders [J].
Jankovic, J ;
Beach, J .
NEUROLOGY, 1997, 48 (02) :358-362
[63]   Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls [J].
Jensen, P ;
Fenger, K ;
Bolwig, TG ;
Sorensen, SA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 65 (04) :467-471
[64]   STUDY OF PSYCHIATRIC MORBIDITY IN PATIENTS WITH HUNTINGTONS-DISEASE, THEIR RELATIVES, AND CONTROLS - ADMISSIONS TO PSYCHIATRIC-HOSPITALS IN DENMARK FROM 1969 TO 1991 [J].
JENSEN, P ;
BOLWIG, TG ;
SORENSEN, SA ;
FENGER, K .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :790-797
[65]   Olanzapine improves chorea inpatients with Huntington's disease [J].
Jiménez-Jiménez, FJ ;
de Toledo, M ;
Puertas, I ;
Barón, M ;
Zurdo, M ;
Barcenilla, B .
REVISTA DE NEUROLOGIA, 2002, 35 (06) :524-525
[66]   Unified Huntington's disease rating scale: Reliability and consistency [J].
Kieburtz, K ;
Penney, JB ;
Como, P ;
Ranen, N ;
Shoulson, I ;
Feigin, A ;
Abwender, D ;
Greenamyre, JT ;
Higgins, D ;
Marshall, FJ ;
Goldstein, J ;
Steinberg, K ;
Shih, C ;
Richard, I ;
Hickey, C ;
Zimmerman, C ;
Orme, C ;
Claude, K ;
Oakes, D ;
Sax, DS ;
Kim, A ;
Hersch, S ;
Jones, R ;
Auchus, A ;
Olsen, D ;
BisseyBlack, C ;
Rubin, A ;
Schwartz, R ;
Dubinsky, R ;
Mallonee, W ;
Gray, C ;
Godfrey, N ;
Suter, G ;
Shannon, KM ;
Stebbins, GT ;
Jaglin, JA ;
Marder, K ;
Taylor, S ;
Louis, E ;
Moskowitz, C ;
Thorne, D ;
Zubin, N ;
Wexler, N ;
Swenson, MR ;
Paulsen, J ;
Swerdlow, N ;
Albin, R ;
Wernette, C ;
Walker, F ;
Hunt, V .
MOVEMENT DISORDERS, 1996, 11 (02) :136-142
[67]   A controlled trial of remacemide hydrochloride in Huntington's disease [J].
Kieburtz, K ;
Feigin, A ;
McDermott, M ;
Como, P ;
Abwender, D ;
Zimmerman, C ;
Hickey, C ;
Orme, C ;
Claude, K ;
Sotack, J ;
Greenamyre, JT ;
Dunn, C ;
Shoulson, I .
MOVEMENT DISORDERS, 1996, 11 (03) :273-277
[68]  
Kieburtz K, 2001, NEUROLOGY, V57, P397
[69]  
KIEBURTZ K, 2002, HUNTINGTONS DIS, P501
[70]  
KNOWLING MR, 1991, S AFR MED J, V79, P169